GlassScriptPhysician profile
Erin R Martin
NPI 1932440260
$9,049.53
in general payments reported to CMS, 2019-2025
41 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,528 · 2022: $1,996 · 2023: $2,108 · 2024: $1,659 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,526.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,096.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $935.72 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $701.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $587.99 | 2021-2025 | |
| Pfizer INC. | $570.15 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $435.40 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.42 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $357.09 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $311.51 | 2021-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.09 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $261.57 | 2021-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $239.74 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $229.62 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $195.41 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $139.76 | 2022-2025 | Gvoke Hypopen, Keveyis |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.